Wörwag Pharma GmbH & Co. KG is a German pharmaceutical company headquartered in Böblingen near Stuttgart with more than 20 international subsidiaries in Asia, Europe and South America. In 2021, the company generated sales of 269,9 million euros with more than 1,200 employees worldwide.
The company develops, produces and distributes pharmaceuticals for the prevention and treatment of lifestyle diseases. Wörwag Pharma is particularly committed to the clinical use of biofactors - which include vitamins, minerals and trace elements - in the prevention and treatment of primarily age-related diseases, such as diabetes mellitus.
Wörwag Pharma's product range includes products subject to prescription as well as over-the-counter products and nutritional supplements. A large proportion of the pharmacy-exclusive products are used to treat diabetic secondary diseases. Other solutions are effective against disorders of the nervous system (neuropathies), strengthen the immune system or support the maintenance of a healthy musculoskeletal system.
Wörwag Pharma manufactures both its own products and contract pharmaceuticals at the production site at Lódz Special Economic Zone, Poland. The modern building complex covers an area of 9,500 square meters and is equipped with cutting-edge technology for production and development. The recently acquire site is being developed into a center of excellence for oral dosage forms for the Wörwag Pharma group of companies.
The family-owned company, founded in 1971 by Dr. Fritz Wörwag, is managed by Dr. Lucia Cinque, Gerhard Mayer and Jochen Schlindwein.